(Q39170296)

9 September 2017

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children (English)

1 reference

9 September 2017

0 references

0 references

1 reference

B Lell

1

1 reference

9 September 2017

D Luckner

2

1 reference

9 September 2017

M Ndjavé

3

1 reference

9 September 2017

T Scott

4

1 reference

9 September 2017

P G Kremsner

5

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

9 September 2017

1 reference

9 September 2017

351

1 reference

9 September 2017

9104

1 reference

9 September 2017

709-713

1 reference

Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants

9 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Atovaquone and proguanil for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Atovaquone and proguanil for the treatment of malaria in Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Confidence limits on the ratio of two Poisson variables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Malarone-donation programme.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

Malarone-donation programme in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2909222-2

7 January 2021

10.1016/S0140-6736(97)09222-2

Identifiers

DOI

1 reference

9 September 2017

1 reference